SG11201700827RA - Powder oral suspension formulations of antibacterial agents - Google Patents

Powder oral suspension formulations of antibacterial agents

Info

Publication number
SG11201700827RA
SG11201700827RA SG11201700827RA SG11201700827RA SG11201700827RA SG 11201700827R A SG11201700827R A SG 11201700827RA SG 11201700827R A SG11201700827R A SG 11201700827RA SG 11201700827R A SG11201700827R A SG 11201700827RA SG 11201700827R A SG11201700827R A SG 11201700827RA
Authority
SG
Singapore
Prior art keywords
antibacterial agents
oral suspension
suspension formulations
powder oral
powder
Prior art date
Application number
SG11201700827RA
Inventor
David Eugene Pereira
Shingai Majuru
Prabhavathi Fernandes
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of SG11201700827RA publication Critical patent/SG11201700827RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
SG11201700827RA 2014-08-05 2015-08-05 Powder oral suspension formulations of antibacterial agents SG11201700827RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033601P 2014-08-05 2014-08-05
US201562173609P 2015-06-10 2015-06-10
PCT/US2015/043774 WO2016022658A1 (en) 2014-08-05 2015-08-05 Powder oral suspension formulations of antibacterial agents

Publications (1)

Publication Number Publication Date
SG11201700827RA true SG11201700827RA (en) 2017-03-30

Family

ID=55264484

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700827RA SG11201700827RA (en) 2014-08-05 2015-08-05 Powder oral suspension formulations of antibacterial agents

Country Status (14)

Country Link
US (2) US20170224664A1 (en)
EP (1) EP3185864A4 (en)
JP (1) JP2017523975A (en)
KR (1) KR20170039689A (en)
CN (1) CN106604729A (en)
AU (1) AU2015301154A1 (en)
BR (1) BR112017002335A2 (en)
CA (1) CA2957034A1 (en)
IL (1) IL250349A0 (en)
MX (1) MX2017001569A (en)
RU (1) RU2017104163A (en)
SG (1) SG11201700827RA (en)
WO (1) WO2016022658A1 (en)
ZA (1) ZA201701487B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917850B (en) 2007-10-25 2016-01-13 森普拉制药公司 The preparation method of macrolide antibacterial agents
WO2010048601A1 (en) 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
RU2658050C2 (en) 2012-03-27 2018-06-19 Семпра Фармасьютикалз, Инк. Parenteral formulations for administering macrolide antibiotics
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US10163241B2 (en) * 2016-12-09 2018-12-25 Microsoft Technology Licensing, Llc Automatic generation of fundus drawings
JP7089855B2 (en) * 2017-10-02 2022-06-23 三栄源エフ・エフ・アイ株式会社 Bitterness masking composition
CN114432241B (en) * 2021-12-21 2023-07-14 上海奥全生物医药科技有限公司 Rapidly-dispersed suspension composition, preparation method and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2821747B1 (en) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques SUSPENSION OF TELITHROMYCIN WITH A MASK TASTE
FR2826274B1 (en) * 2001-06-21 2003-09-26 Aventis Pharma Sa PHARMACEUTICAL FORMULATION FOR MASK TASTE AND METHOD FOR PREPARING THE SAME
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
MXPA05000322A (en) * 2002-07-19 2005-03-31 Aventis Pharma Sa Taste masked oral composition of telithromycin.
WO2004080391A2 (en) * 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
US9814657B2 (en) * 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
PL2544537T3 (en) * 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Parenteral formulations of macrolide antibiotics
KR20180101643A (en) * 2010-03-22 2018-09-12 셈프라 파마슈티컬스, 인크. Crystalline forms of a macrolide, and uses therefor
CA2812044A1 (en) * 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS

Also Published As

Publication number Publication date
KR20170039689A (en) 2017-04-11
RU2017104163A (en) 2018-09-06
US20170224664A1 (en) 2017-08-10
US20190209530A1 (en) 2019-07-11
ZA201701487B (en) 2021-05-26
JP2017523975A (en) 2017-08-24
RU2017104163A3 (en) 2019-02-15
MX2017001569A (en) 2017-08-07
BR112017002335A2 (en) 2018-01-16
EP3185864A1 (en) 2017-07-05
WO2016022658A1 (en) 2016-02-11
EP3185864A4 (en) 2018-03-28
AU2015301154A1 (en) 2017-02-23
IL250349A0 (en) 2017-03-30
CN106604729A (en) 2017-04-26
CA2957034A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
HRP20190173T1 (en) Oral formulations of deferasirox
ZA201701487B (en) Powder oral suspension formulations of antibacterial agents
FI3185853T3 (en) Inhalable powder formulations of alginate oligomers
GB201519088D0 (en) The use of bacteria formulations
IL259044B (en) Oral care compositions
ZA201706785B (en) Oral care compositions
ZA201803909B (en) Oral care compositions
IL272857A (en) Formulations of copanlisib
ZA201700518B (en) Use of active compound compositions
EP3265177C0 (en) Formulations of hydrophilic compounds
SG11201708597VA (en) Oral care composition
IL267279A (en) Pharmaceutical formulations of suvorexant
IL258305A (en) Oral care compositions
ZA201800096B (en) Oral care compositions
IL252447A0 (en) Oral care composition
PT3678644T (en) Formulations of copanlisib
ZA201801992B (en) Oral care compositions
GB201611600D0 (en) Novel formulations of valsartan
GB201611620D0 (en) Novel formulations of valsartan
IL252994A0 (en) Oral care composition
ZA201700064B (en) Pharmaceutical compositions comprising antibacterial agents
GB201506705D0 (en) Oral suspension
GB201417646D0 (en) Formulations of phosphate derivatives
GB201403170D0 (en) Preparation of antibacterial bisbenzimidazoles